Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uropathogenic Escherichia coli (UPEC) is a specialized pathotype of the bacterium *Escherichia coli* that is the primary causative agent of urinary tract infections (UTIs), responsible for 80–90% of community-acquired cases. UPEC possesses unique virulence factors enabling it to colonize, invade, and persist within the urinary tract, leading to a range of clinical manifestations from mild cystitis to severe pyelonephritis and urosepsis. A major clinical challenge is rising antibiotic resistance, complicating treatment options.
Varies depending on the antibiotic or therapy. Beta-lactams inhibit cell wall synthesis. Phage therapy uses bacteriophages to infect and lyse bacteria. Nanomaterials may disrupt bacterial membranes or deliver antimicrobial agents.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uropathogenic Escherichia coli (UPEC).